Literature DB >> 26202258

PACAP Modulates Expression of Hypoxia-Inducible Factors in Streptozotocin-Induced Diabetic Rat Retina.

Agata Grazia D'Amico1, Grazia Maugeri1, Rita Reitano1, Claudio Bucolo2, Salvatore Saccone3, Filippo Drago2, Velia D'Agata4,5.   

Abstract

Retinal hypoxia has been related to the pathogenesis of diabetic retinopathy. This event is mediated by the hypoxia-inducible factors (HIFs), including HIF-1α, HIF-2α, and HIF-3α. Previously, we have demonstrated the protective role of pituitary adenylate cyclase-activating peptide (PACAP) in the early phase of diabetic retinopathy. In the present work, we investigated whether PACAP effect in hyperglycemic retina is mediated through modulation of HIFs' expression. Diabetes was induced with a single injection of streptozotocin (STZ) in rats. After 1 week, a group of diabetic animals was treated with a single intravitreal injection of 100 μM PACAP or saline solution. Then, changes in HIFs' expression levels were evaluated in the retina after 3 weeks of hyperglycemia. The expression of HIF-1α and HIF-2α was significantly (p < 0.001 vs control) increased in diabetic rats as compared to controls. Instead, their expression levels were significantly (p < 0.001 vs STZ) decreased after PACAP intraocular administration, as detected by Western blot analysis. Conversely, the expression of HIF-3α was significantly (p < 0.001 vs control) downregulated in retinas of STZ-injected rats and significantly (p < 0.001 vs control) increased after PACAP treatment. These data were supported by the immunohistochemical analysis. HIFs were localized either in inner and outer retinal layers. Diabetes interferes with their distribution, which is changed following intravitreal injection of PACAP. The present results suggest that the protective effect of the peptide in diabetic retina might be also mediated through modulation of HIFs' expression.

Entities:  

Keywords:  Diabetic retinopathy; Hypoxia-inducible factors; PACAP; STZ-injected rats

Mesh:

Substances:

Year:  2015        PMID: 26202258     DOI: 10.1007/s12031-015-0621-7

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  58 in total

1.  Is glycemic control improving in U.S. adults?

Authors:  Thomas J Hoerger; Joel E Segel; Edward W Gregg; Jinan B Saaddine
Journal:  Diabetes Care       Date:  2007-10-12       Impact factor: 19.112

2.  HIF-1 is involved in high glucose-induced paracellular permeability of brain endothelial cells.

Authors:  Jingqi Yan; Ziyan Zhang; Honglian Shi
Journal:  Cell Mol Life Sci       Date:  2011-05-27       Impact factor: 9.261

3.  Human HIF-3alpha4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma.

Authors:  Mindy A Maynard; Andrew J Evans; Tomoko Hosomi; Shuntaro Hara; Michael A S Jewett; Michael Ohh
Journal:  FASEB J       Date:  2005-09       Impact factor: 5.191

4.  Regulation of hypoxia-inducible factor (HIF)-1 activity and expression of HIF hydroxylases in response to insulin-like growth factor I.

Authors:  Caroline Treins; Sophie Giorgetti-Peraldi; Joseph Murdaca; Marie-Noëlle Monthouël-Kartmann; Emmanuel Van Obberghen
Journal:  Mol Endocrinol       Date:  2005-02-03

5.  Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells.

Authors:  Masaaki Seki; Takayuki Tanaka; Hiroyuki Nawa; Tomoaki Usui; Takeo Fukuchi; Kazuhito Ikeda; Haruki Abe; Nobuyuki Takei
Journal:  Diabetes       Date:  2004-09       Impact factor: 9.461

6.  Ameliorative effect of PACAP and VIP against increased permeability in a model of outer blood retinal barrier dysfunction.

Authors:  Soraya Scuderi; Agata Grazia D'Amico; Alessandro Castorina; Rosa Imbesi; Maria Luisa Carnazza; Velia D'Agata
Journal:  Peptides       Date:  2012-12-05       Impact factor: 3.750

Review 7.  Neuropeptides and diabetic retinopathy.

Authors:  Robert Gábriel
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

8.  PACAP-mediated neuroprotection of neurochemically identified cell types in MSG-induced retinal degeneration.

Authors:  Tamas Atlasz; Krisztina Szabadfi; Peter Kiss; Norbert Babai; Zsombor Koszegi; Andrea Tamas; Dora Reglodi; Robert Gabriel
Journal:  J Mol Neurosci       Date:  2008-04-17       Impact factor: 3.444

9.  NAP reduces murine microvascular endothelial cells proliferation induced by hyperglycemia.

Authors:  Agata Grazia D'Amico; Soraya Scuderi; Grazia Maugeri; Sebastiano Cavallaro; Filippo Drago; Velia D'Agata
Journal:  J Mol Neurosci       Date:  2014-05-30       Impact factor: 3.444

10.  Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1.

Authors:  G L Semenza; B H Jiang; S W Leung; R Passantino; J P Concordet; P Maire; A Giallongo
Journal:  J Biol Chem       Date:  1996-12-20       Impact factor: 5.157

View more
  20 in total

1.  Proteomic Analysis of Parkin Isoforms Expression in Different Rat Brain Areas.

Authors:  Agata Grazia D'Amico; Grazia Maugeri; Rita Reitano; Sebastiano Cavallaro; Velia D'Agata
Journal:  Protein J       Date:  2016-10       Impact factor: 2.371

2.  Nap Interferes with Hypoxia-Inducible Factors and VEGF Expression in Retina of Diabetic Rats.

Authors:  Agata Grazia D'Amico; Grazia Maugeri; Claudio Bucolo; Salvatore Saccone; Concetta Federico; Sebastiano Cavallaro; Velia D'Agata
Journal:  J Mol Neurosci       Date:  2016-12-01       Impact factor: 3.444

3.  The Protective Role of PAC1-Receptor Agonist Maxadilan in BCCAO-Induced Retinal Degeneration.

Authors:  A Vaczy; D Reglodi; T Somoskeoy; K Kovacs; E Lokos; E Szabo; A Tamas; T Atlasz
Journal:  J Mol Neurosci       Date:  2016-08-26       Impact factor: 3.444

4.  PACAP Is Protective in a Rat Model of Retinopathy of Prematurity.

Authors:  Timea Kvarik; Barbara Mammel; Dora Reglodi; Krisztina Kovacs; Dora Werling; Brigitta Bede; Alexandra Vaczy; Eszter Fabian; Gabor Toth; Peter Kiss; Andrea Tamas; Tibor Ertl; Judit Gyarmati; Tamas Atlasz
Journal:  J Mol Neurosci       Date:  2016-08-25       Impact factor: 3.444

5.  Pituitary Adenylate Cyclase Activating Polypeptide, A Potential Therapeutic Agent for Diabetic Retinopathy in Rats: Focus on the Vertical Information Processing Pathway.

Authors:  K Szabadfi; D Reglodi; A Szabo; B Szalontai; A Valasek; Gy Setalo; P Kiss; A Tamas; M Wilhelm; R Gabriel
Journal:  Neurotox Res       Date:  2016-01-06       Impact factor: 3.911

Review 6.  Matrix metalloproteinase 14 modulates diabetes and Alzheimer's disease cross-talk: a meta-analysis.

Authors:  Jack Cheng; Hsin-Ping Liu; Cheng-Chun Lee; Mei-Ying Chen; Wei-Yong Lin; Fuu-Jen Tsai
Journal:  Neurol Sci       Date:  2017-11-04       Impact factor: 3.307

Review 7.  PACAP and NAP: Effect of Two Functionally Related Peptides in Diabetic Retinopathy.

Authors:  Agata Grazia D'Amico; Grazia Maugeri; Giuseppe Musumeci; Dora Reglodi; Velia D'Agata
Journal:  J Mol Neurosci       Date:  2021-01-05       Impact factor: 3.444

Review 8.  Photoreceptor cells and RPE contribute to the development of diabetic retinopathy.

Authors:  Deoye Tonade; Timothy S Kern
Journal:  Prog Retin Eye Res       Date:  2020-11-12       Impact factor: 19.704

9.  Passage through the Ocular Barriers and Beneficial Effects in Retinal Ischemia of Topical Application of PACAP1-38 in Rodents.

Authors:  Dora Werling; William A Banks; Therese S Salameh; Timea Kvarik; Laszlo Akos Kovacs; Alexandra Vaczy; Edina Szabo; Flora Mayer; Rita Varga; Andrea Tamas; Gabor Toth; Zsolt Biro; Tamas Atlasz; Dora Reglodi
Journal:  Int J Mol Sci       Date:  2017-03-21       Impact factor: 5.923

10.  Diabetes Affects the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)-Like Immunoreactive Enteric Neurons in the Porcine Digestive Tract.

Authors:  Katarzyna Palus; Michał Bulc; Jarosław Całka; Łukasz Zielonka; Marcin Nowicki
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.